High Net Worth Advisory Group’s Bicycle Therapeutics BCYC Stock Holding History

High Net Worth Advisory Group’s Portfolio BCYC Stock Details BCYC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-500	Closed	-$8K	–	681
2022 Q2	$8K	Hold	500	–	–	﹤0.01%	546
2022 Q1	$22K	Hold	500	–	–	0.01%	439
2021 Q4	$30K	Buy	+500	New	+$27.6K	0.01%	404

Other funds holding BCYC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Samlyn Capital New York $6.14B AUM 42.05% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $22.2B AUM 58.34% 1-Year Est. Return

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

TCM

Tybourne Capital Management Hong Kong $30.9M AUM 20.1% 1-Year Est. Return

SHI

SV Health Investors Boston, Massachusetts $32.3M AUM 20.15% 1-Year Est. Return

High Net Worth Advisory Group's BCYC Position: Q3 2022 in Review

High Net Worth Advisory Group sold out of Bicycle Therapeutics (BCYC) in Q3 2022, closing a stake of 500 shares — an estimated $8K sold.

High Net Worth Advisory Group first reported a position in BCYC in Q4 2021 and held it in 3 quarters. The position peaked at $30K in Q4 2021. 79 funds tracked by Wall St. Rank hold BCYC as of Q3 2022.

High Net Worth Advisory Group reported no remaining Bicycle Therapeutics position as of Q3 2022 after selling out during the quarter.
High Net Worth Advisory Group sold 500 Bicycle Therapeutics shares in Q3 2022, an estimated $8K.
High Net Worth Advisory Group first reported a position in Bicycle Therapeutics in Q4 2021 and held it in 3 quarters.
High Net Worth Advisory Group's Bicycle Therapeutics position peaked at $30K in Q4 2021.
79 funds tracked by Wall St. Rank held Bicycle Therapeutics as of Q3 2022.

Based on High Net Worth Advisory Group's 13F filing for Q3 2022, filed 24 Oct 2022.